Pharmaceuticals

The Rising Prevalence Of Genetic Disorders Is Fueling The Growth Of The Market Due To Increasing Cases That Require Targeted, Gene-Based Therapies Is Supporting Development Across The Personalized Gene Therapy Treatment Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Personalized Gene Therapy Treatment Market During 2026–2030?

The personalized gene therapy treatment market has seen substantial growth in recent years. This market is expected to expand from $8.38 billion in 2025 to $10.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.7%. The historical growth of the market is primarily attributable to the increasing prevalence of genetic disorders, advancements in genomic sequencing technologies, early clinical success of targeted gene therapies, the expansion of specialized gene therapy research centers, and increasing investment in precision medicine.

The personalized gene therapy treatment market is projected to experience rapid expansion over the coming years. It is forecast to reach a valuation of $21.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 20.4%. This anticipated growth during the forecast period is propelled by factors such as a rise in regulatory clearances for personalized gene therapies, increased demand for tailored oncology solutions, broader capabilities in gene therapy manufacturing, growing incorporation of artificial intelligence in therapy development, and wider acceptance of treatments guided by pharmacogenomics. Key developments shaping the market during this period encompass the escalating embrace of gene editing-based therapies, an uptick in the application of personalized treatment regimens, enhanced integration of companion diagnostics, the advancement of both viral and non-viral vector platforms, and a heightened emphasis on precision oncology applications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28293&type=smp

What Important Drivers Are Powering The Personalized Gene Therapy Treatment Market Growth?

The increasing occurrence of genetic disorders is projected to fuel the expansion of the personalized gene therapy treatment market in the future. These conditions arise from DNA irregularities that impair typical bodily functions. The frequency of genetic disorders is escalating, primarily attributed to advanced parental age, as older reproductive cells are more susceptible to mutations that can be inherited by descendants. Personalized gene therapy targets genetic disorders by precisely mending the faulty genes causing the condition, customizing treatment to an individual’s unique genetic profile, which boosts effectiveness and lessens adverse reactions. A case in point is the data from October 2024, where the Cystic Fibrosis Trust, a UK-based charity aiding individuals with cystic fibrosis, reported approximately 11,148 registered cystic fibrosis (a genetic disorder) patients in 2022. This figure increased to 11,318 in 2023, showing a 1.5% year-over-year rise in patient registrations. Consequently, the rising incidence of genetic disorders is propelling the growth of the personalized gene therapy treatment market.

What Segment Categories Are Evaluated In The Personalized Gene Therapy Treatment Market Study?

The personalized gene therapy treatment market covered in this report is segmented –

1) By Therapy: Targeted Treatments, Pharmacogenomics

2) By Vector Type: Viral, Non-Viral

3) By Distribution Channel: Hospitals, Clinics, Home Administration, Other Distribution Channels

4) By Application: Oncology, Neurology, Hematological, Infectious Diseases, Ophthalmology, Other Applications

Subsegments:

1) By Targeted Treatments: Monoclonal Antibodies, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), Small Interfering RNA (siRNA) Therapy, Antisense Oligonucleotides (ASO), Gene Editing Therapy

2) By Pharmacogenomics: Companion Diagnostics, Drug Metabolism Enzyme Testing, Genetic Biomarker Analysis, Single Nucleotide Polymorphism (SNP) Profiling, Adverse Drug Reaction (ADR) Prediction

What Trends Are Shaping The Personalized Gene Therapy Treatment Market Structure?

Leading companies within the personalized gene therapy treatment market are increasingly focusing on forming strategic partnerships to enhance their technological capabilities and accelerate the delivery of innovative therapies to patients. These strategic partnerships are collaborative alliances forged between organizations to harness each other’s strengths and resources, aiming for mutual growth and a competitive advantage, while also sharing associated risks and benefits. A notable illustration occurred in May 2025, when Aldevron, a US-based firm specializing in the production of DNA, RNA, and protein, collaborated with Integrated DNA Technologies, a US-based supplier of genomics solutions. Their joint effort led to the manufacturing of the world’s first mRNA-based personalized CRISPR therapy, designed to treat an infant afflicted with urea cycle disorder (UCD), a rare and life-threatening genetic condition. This unique N of 1 therapy was conceived and delivered in a mere six months through the creation of a custom guide RNA, an mRNA-encoded base editor, off-target safety services, and a clinically validated lipid nanoparticle delivery system. The successful development of this therapy marks a considerable milestone in the field of personalized in vivo base-editing treatments.

Which Firms Are Competing In The Personalized Gene Therapy Treatment Market?

Major companies operating in the personalized gene therapy treatment market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

Access The Complete Personalized Gene Therapy Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-gene-therapy-treatment-global-market-report

Which Region Contributes The Most To The Personalized Gene Therapy Treatment Market?

North America was the largest region in the personalized gene therapy treatment market in 2025. The regions covered in the personalized gene therapy treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Personalized Gene Therapy Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=28293&type=smp

Browse Through More Reports Similar to the Global Personalized Gene Therapy Treatment Market 2026, By The Business Research Company

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Nucleic Acid Based Gene Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795